Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

bottles of Roundup

The active ingredient in RoundUp is glyphosate, which the World Health Organization classifies as a probable human carcinogen. (Photo: Mike Mozart/Flickr/cc)

Trump's EPA Goes to Bat for Bayer as Company Fights $25 Million Verdict in Roundup Cancer Case

The chemical company is asking a federal appeals court to reverse its ruling in favor of a California man suffering from non-Hodgkin's lymphoma.

Andrea Germanos

President Donald Trump's Environmental Protection Agency—already accused of being "pesticide cheerleader"—threw its weight behind chemical company Bayer AG on Friday when the agency asked a federal appeals court to reverse a lower court's ruling in favor of a man who said the company's Roundup weedkiller was responsible for his cancer.

The case centers on Edwin Hardeman of California, who was diagnosed with non-Hodgkin's lymphoma in 2015 after using the glyphosate-based pesticide, made by Monsanto, for years on his property. Bayer acquired Monsanto last year.

A federal jury in July ordered the company to pay Hardeman roughly $25 million in damages, a lower amount than the $80 million a federal judge had ordered months earlier.

The EPA maintains—to the outrage of environmental and public health groups—that glyphosate is not a carcinogen. The federal decision notwithstanding, California in 2017 agreed with the World Health Organization's 2015 classification of glyphosate as a "probable carcinogen." Trump's EPA has pushed back on the state's finding and said that product labels informing users of that cancer risk would "misbranding" and announced in August of this year that the agency would not approve of labels carrying that warning.

In an amicus brief filed Friday with the U.S. Court of Appeals for the Ninth Circuit, attorneys with the EPA and Justice Department said,

EPA approved the label for the pesticide/herbicide at issue here, Roundup, through a registration process that did not require a cancer warning. In fact, EPA has never required a labeling warning of a cancer risk posed by Roundup, and such a warning would be inconsistent with the agency's scientific assessments of the carcinogenic potential of the product. Mr. Hardeman nevertheless sought damages under California common law, alleging that Monsanto had failed to adequately warn consumers of cancer risks posed by the active ingredient in Roundup. FIFRA therefore preempts Mr. Hardeman's claims to the extent that they are based on the lack of a warning on Roundup's labeling. 

The filing from the federal government came the same week Bayer AG asked the appeals court to toss out the lower court's ruling and defended Roundup's safety.

Bayer is currently facing nearly 43,000 claims related to glyphosate-linked cancer in federal courts. An end to the company's legal woes is unlikely to happen soon, according to Bloomberg Environment.

"The only vehicle that remotely approaches [an end to litigation] might be bankruptcy," Loyola Law School professor Adam Zimmerman told the outlet last week. "Short of that, or some victories in court, I don't see what kind of arrangement would absolve them of future liability."


Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.

We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.

Sanders Demands End to Medicare Premium Hike From Alzheimer's Drug

Biogen's original price for the controversial drug, he argues, "is the perfect example of why Medicare should be negotiating drug prices with the pharmaceutical industry."

Jessica Corbett ·


'Monumental Victory' as Biden Cancels Boundary Waters Mining Leases

Rep. Betty McCollum called the administration's decision "a rejection of the deeply flawed and politically motivated process under the Trump administration."

Brett Wilkins ·


Rights Groups Demand Hearings on the 'Fourth Amendment Is Not For Sale Act'

"The longer Congress waits," warned one advocate, "the stronger and more dangerous this industry will become."

Kenny Stancil ·


Democrats Urge Biden to Abandon Dangerous Trump Policies on Nuclear Weapons

With the Nuclear Posture Review, say congressional lawmakers, the president can ensure "future generations can finally be free from the nuclear sword of Damocles that hangs over all our heads."

Andrea Germanos ·


'There Is No Military Solution': Jayapal, Lee Demand Diplomacy on Ukraine

"We call upon our colleagues to allow the administration to find a diplomatic way out of this crisis," said the progressive Democrats.

Jake Johnson ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.


Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo